SCHEMBL1735866

SCHEMBL1735866

CC(O)n1c[c]cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL603440 0.69
SCHEMBL1712110 0.68
SCHEMBL16050877 0.67
SCHEMBL2520858 0.65
SCHEMBL1712963 0.65
SCHEMBL9443043 0.63
SCHEMBL6630589 0.60
SCHEMBL4350685 0.56
SCHEMBL5329145 0.54
Isopropyl Alcohol SCHEMBL1236799 0.51 ALDH1A1 (0.86)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9102669-B2 Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-08-11 US claimed
US-20140371220-A1 SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-12-18 US claimed
WO-2013085957-A1 SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2013-06-13 WO claimed
US-20240156792-A1 COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-05-16 US disclosed
US-11918562-B2 Combination therapy using azabicyclo compound for cancer TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-03-05 US disclosed
US-20220016090-A1 COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER TAIHO PHARMACEUTICAL CO., LTD. (JP) 2022-01-20 US disclosed
US-11166943-B2 Combination therapy using azabicyclo compound for cancer TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-11-09 US disclosed
US-10849886-B2 Combination therapy using azabicyclo compound for cancer TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-01 US disclosed
US-20200281904-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES INVOLVING IDO EXPRESSION TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-09-10 US disclosed
US-20200276171-A1 COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-09-03 US disclosed
EP-3682900-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES INVOLVING IDO EXPRESSION Taiho Pharmaceutical Co., Ltd. (JP) 2020-07-22 EP disclosed
EP-1931676-B1 Pyrazolopyrimidines as protein kinase inhibitors SCHERING CORP (US) 2011-11-16 EP disclosed
US-7776865-B2 Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors SCHERING CORPORATION (US) 2010-08-17 US disclosed
US-20100125068-A1 METHODS FOR INHIBITING PROTEIN KINASES SCHERING CORPORATION 2010-05-20 US disclosed
EP-1942900-A2 USE OF PYRAZOLO [1,5-A] PYRIMIDINE DERIVATIVES FOR INHIBITING KINASES METHODS FOR INHIBITING PROTEIN KINASES SCHERING CORPORATION (US) 2008-07-16 EP disclosed
EP-1931676-A1 PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2008-06-18 EP disclosed
WO-2007044441-A2 USE OF PYRAZOLO [1 , 5 -A] PYRIMIDINE DERIVATIVES FOR INHIBITING PROTEIN KINASES METHODS FOR INHIBITING PROTEIN KINASES SCHERING CORPORATION (US) 2007-04-19 WO disclosed
US-20070082900-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-04-12 US disclosed
US-20070083044-A1 Pyrazolopyrimidines as protein kinase inhibitors SCHERING CORPORATION 2007-04-12 US disclosed
WO-2007041712-A1 PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2007-04-12 WO disclosed